Developing a therapeutic innovation which revolutionises conventional approaches

Nanobiotix is a company specialised in nanomedicine. It develops nanoparticles which penetrate cancerous tumours and maximise the positive effects of radiotherapy. Important progress could be made in this field, and this approach could represent an alternative to the long and costly development of new therapeutic molecules. It has been ten years since this NanoXray technology was heralded by the Herald Tribune as the ‘break-through technology for the next decade’. Since then, there has been one human clinical study whose preliminary results should be known by the end of 2012. It is often difficult for radical innovations to find financing and the necessary support to make their mark, but the team at Nanobiotix made sure that its innovation was designed in such a way that it only very marginally upsets existing medical practices and at the same time offers safety, efficiency and guarantees intellectual property. These factors make it very attractive. Nanobiotix now has to overcome the difficult stage of finding partners to develop its product, carry out clinical studies, and market it throughout the world.